IC-8 Intraocular Lens (IOL)
DeviceA small aperture extended depth of focus hydrophobic acrylic intraocular lens.
Other names: IC-8 IOL
NCT Number: NCT05574270
The objective of this study is to evaluate the clinical outcomes of the IC-8 IOL implanted in patients with complex corneas after crystalline lens removal.
Looking for future studies?
Notify Me22 year and older
All sexes
Interventional
Not applicable
Asian Eye Institute, Makati City, Philippines
This is a prospective, multi-center, open-label, non-randomized, single-arm clinical investigation with planned postoperative follow-up of 4-6 months. The monocular and binocular performance of the subjects will be evaluated.
The objective of this study is to evaluate the clinical outcomes of the IC-8 IOL implanted in patients with complex corneas after crystalline lens removal.
The co-primary effectiveness endpoints are monocular uncorrected distance, intermediate, and near visual acuities at 4-6 Months postoperative. The primary safety endpoint is best-corrected distance visual acuity at 4-6 Months postoperative. The secondary safety endpoint is photopic and mesopic contrast sensitivity at 4-6 Months postoperative.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
Other names: IC-8 IOL
Time frame: 4-6 Months
Mean acuity from the IC-8 IOL eye at 4-6 Months is statistically better compared to preoperative
Time frame: 4-6 Months
Mean acuity from the IC-8 IOL eye at 4-6 Months is statistically better compared to preoperative
Time frame: 4-6 Months
Mean acuity from the IC-8 IOL eye at 4-6 Months is statistically better compared to preoperative
Time frame: 4-6 Months
Mean best-corrected distance visual acuity (BCDVA) in the IC-8 IOL eye at 4-6 Months is not statistically worse than 0.2 logMAR
Time frame: 4-6 Months
Photopic and Mesopic contrast sensitivity (with and without glare) in each eye and both eyes will be analyzed. No success criterion or hypothesis testing.
AcuFocus, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05411341
Cataract, Eye Diseases
Alexandroupoli, Evros, Greece
View Trial DetailsNCT06460389
Cataract, Eye Diseases
Alexandroupoli, Evros, Greece
View Trial DetailsNCT07385014
Cataract, Eye Diseases
Hershey, Pennsylvania, United States
View Trial DetailsNCT06642779
Ametropia, Cataract
Miskolc, BAZ Vármegye, Hungary
View Trial Details